Illumina to divest cancer test maker Grail after antitrust battles

Illumina to divest cancer test maker Grail after antitrust battles | Reuters

Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and ...

Illumina to Shed Cancer-Test Maker Grail After Antitrust Battle - WSJ

Gene-sequencing company Illumina ILMN -2.62%decrease; red down pointing triangle said Sunday it will divest itself of cancer blood test ...

Statement Regarding Illumina's Decision to Divest Grail

Illumina's decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality ...

EC Approves Illumina's Plan to Divest Cancer Diagnostics Maker Grail

After a years-long antitrust battle, the European Commission on Friday approved Illumina's plans to divest Grail ... cancer detection tests ...

Illumina to divest cancer test maker Grail - New York Post

Illumina said on Sunday that it would divest cancer diagnostic test maker Grail after the companies battled both US and European antitrust ...

Illumina's Antitrust Battles to End With Divestiture of Cancer Test ...

Illumina's Antitrust Battles to End With Divestiture of Cancer Test Maker Grail ... Illumina has decided against further appeals of U.S. and ...

Illumina to Divest Cancer Test Maker Grail After Antitrust Battles

Grail, valued at $7.1 billion under Illumina's deal, is seeking to market a blood test that can diagnose many kinds of cancer, known as a liquid ...

Illumina wins Grail battle in blow to EU merger power | Reuters

... cancer diagnostic test maker Grail (GRAL.O) , opens new tab, a ruling set to curb Brussels' merger powers. Illumina, which founded Grail and ...

FTC Orders Illumina to Divest Cancer Detection Test Maker GRAIL ...

Real world evidence of Illumina's past behavior reinforces the Commission's antitrust concerns. For instance, Illumina gave GRAIL special ...

Roundup: Illumina's long goodbye to cancer test maker Grail

The DNA sequencing leader has been dealing with the fallout of that decision ever since, as regulators in both the U.S. and Europe turned up the ...

Illumina to divest cancer test maker Grail after antitrust battles

(Reuters) - Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and ...

Genetic sequencing company Illumina to divest cancer ... - Axios

Genetic sequencing giant Illumina will finally divest cancer diagnostic test maker Grail after two years of battling with antitrust regulators.

Illumina Loses Long Antitrust Battle, Readies to Divest GRAIL

Illumina on Sunday announced that it would divest cancer testing company GRAIL following a drawn-out antitrust battle with regulators in Europe and the US.

Latest News - Illumina to divest cancer test maker Grail...

Illumina to divest cancer test maker Grail after antitrust battles. Thumbnail, https://www.rtbnews.rtb.gov.bn/SiteCollectionImages/. Video.

Illumina-Grail $8B Saga Ends After It Battles Regulators For 3 Years

On Sunday, gene-sequencing company Illumina Inc (NASDAQ: ILMN) agreed to divest cancer diagnostic test maker Grail Inc as the companies ...

Illumina to part with Grail, ending battle with regulators | MedTech Dive

DNA sequencing company Illumina said Sunday it will divest Grail, the liquid biopsy maker it fought to hang onto after purchasing the ...

Illumina to divest Grail, following court's decision to uphold FTC order

Illumina announced it would be divesting cancer test maker Grail, following a battle with antitrust regulators over the $7.1 billion ...

Illumina-Grail - United States Court of Appeals for the Fifth Circuit

... test—for vertical mergers in modern antitrust analysis. ... are, right now, working on creating tests that will rival Grail's capabilities and.

Illumina Announces Decision to Divest GRAIL

On December 15, the U.S. Fifth Circuit Court of Appeals issued its decision in the matter of Illumina v. the Federal Trade Commission. Following ...

FTC Orders Illumina to Divest GRAIL - Maryland Carey Law

The FTC ordered Illumina, a DNA sequencing provider, to divest GRAIL, a cancer detection test developer, to ensure that the race to develop and bring to market ...